Buffett InvestorsNZX
Back
EBO.NZ

Ebos Group Down 38% in a Year — Analysts Say It's a Buy With 47% Upside

The NZX's Fallen Healthcare Giant

Ebos Group (NZX: EBO) has had a brutal 12 months. The share price has dropped roughly 38% over the past year, falling from above $38 to around $24.40 NZD — making it one of the worst performers among large-cap NZX stocks. For a company that spent the better part of a decade as a reliable compounder in Australasian healthcare distribution, the selloff has been jarring. Yet here's the thing that makes Ebos Group NZX stock interesting right now: every analyst covering the stock rates it a Buy, with an average price target implying nearly 47% upside from current levels.

So who's right — the market or the analysts?

Recent Performance: A Stock in Freefall

The numbers don't make for comfortable reading if you've been holding:

  • •Current price: ~$24.40 NZD
  • •12-month decline: -38%
  • •Year-to-date decline: -18%

Ebos has underperformed both the NZ Healthcare sector (down 29% over the same period) and the broader NZ Market (up 3.4%). Weekly volatility has held steady at around 4%, so this hasn't been a dramatic crash — more of a slow, grinding slide that's eroded a third of the company's value.

Key Metrics at a Glance

  • •Market cap: ~$4.96 billion NZD
  • •P/E ratio: ~14.9x (trailing), ~14.3x (forward)
  • •Dividend yield: ~5.3–5.8%
  • •EPS (TTM): $1.09 NZD
  • •EPS (forward consensus): A$1.31
  • •Payout ratio: ~82% (3-year smoothed)
  • •Price-to-sales: 0.31x

At under 15x earnings and a P/S ratio of just 0.31x, Ebos is trading at a significant discount to its historical multiples. The 5.3% dividend yield is well above what the stock typically offered during its growth years, which tells you the market is pricing in lower expectations.

The Big Picture: Healthcare Distribution Powerhouse

Ebos is Australasia's largest healthcare, medical, and pharmaceutical distributor. If you've picked up a prescription in New Zealand or Australia, there's a good chance Ebos was somewhere in the supply chain. The company operates through two main segments:

Healthcare — the core business, generating $6.3 billion in H1 FY2026 revenue (up 11%). Growth has been driven by the distribution of GLP-1 weight-loss drugs and other high-value medicines, plus expansion of its retail pharmacy brands and medical technology arm. The catch? These newer drug categories carry lower margins, which is pressuring profitability even as revenue grows.

Animal Care — the standout performer, with revenue surging 48% to $451 million and EBITDA up 15% to $68 million. This segment, bolstered by acquisitions, is becoming an increasingly important part of the Ebos story.

The H1 FY2026 result told the story in a nutshell: revenue up 13% to $6.8 billion, underlying EBITDA up a more modest 3.2% to $300 million, and underlying net profit actually down 4.3% to $125 million. The company is growing the top line but struggling to convert that into bottom-line gains — and that's exactly what the market is punishing.

What to Watch

  • •Margin recovery: The key question for Ebos. GLP-1 drug distribution is high-volume but low-margin. If the company can improve margins on these products — or if the mix shifts back toward higher-margin categories — earnings should follow.
  • •Animal Care momentum: The 48% revenue growth and margin expansion in this segment is a genuine bright spot. Continued execution here provides a growth lever independent of healthcare headwinds.
  • •Acquisition integration: Ebos has been active on the M&A front. Successfully integrating recent New Zealand and Australian acquisitions will be critical to delivering on full-year guidance.
  • •Analyst targets: The consensus sits at $36–37 NZD, with a high estimate of $41 NZD and a low of $30 NZD. Six analysts recommend Buy, zero say Sell. That level of unanimity is notable, but analysts have also been trimming their targets after the latest results (down 6.5% on average).
  • •Full-year guidance: Management reaffirmed FY2026 guidance, implying a stronger second half with EBITDA lifting to around A$325 million. Hitting this number is essential to rebuilding market confidence.

The Bottom Line

Ebos Group is a high-quality healthcare distributor going through a rough patch, caught between strong revenue growth and margin compression from lower-margin drug categories. The 38% decline has created a valuation that's cheap by historical standards, and the analyst consensus strongly suggests the selloff has been overdone. But until margins start recovering, the share price may continue to drift. This looks like a classic case where patience could pay off handsomely — but timing the turnaround is the hard part.

*This article is for informational purposes only and does not constitute financial advice. Always conduct your own research or consult a licensed financial adviser before making investment decisions. Past performance is not indicative of future results.*